First People's Hospital

This program combines three established therapeutic agents—iron sucrose (VENOFER), human erythropoietin injection, and vitamin C—for the treatment of anemia. Iron sucrose is an intravenous iron replacement therapy approved globally; erythropoietin stimulates red blood cell production; vitamin C enhances iron absorption. The sponsor is The First People's Hospital of Lianyungang, a Chinese institution. The program is currently active with a latest milestone recorded on 2025-04-16, though specific milestone details are not yet disclosed. Iron sucrose itself carries extensive regulatory approval history, with US FDA approvals dating to the NDA stage and Australian TGA listings since 2005. The clinical investigation is registered under NCT06012760. Development phase information is not yet disclosed. This represents a combination approach to anemia management leveraging well-established individual components rather than a novel molecular entity.

Anemia remains a significant clinical burden globally, particularly in patients with chronic kidney disease, cancer, and other chronic conditions. Iron deficiency anemia and anemia of chronic disease affect hundreds of millions of patients worldwide. The combination of iron supplementation, erythropoiesis-stimulating agents, and vitamin C addresses multiple pathophysiological mechanisms of anemia simultaneously. Iron sucrose has long been the standard-of-care intravenous iron formulation due to its favorable safety profile compared to earlier iron dextran formulations. The addition of vitamin C as an adjunctive agent may enhance iron bioavailability and efficacy. Market relevance is substantial given the prevalence of anemia across multiple therapeutic domains and the ongoing clinical need for optimized treatment regimens. Competitive positioning against established monotherapies and combination approaches will depend on demonstrated clinical efficacy, safety, and convenience. The patient population is broad, spanning dialysis-dependent chronic kidney disease patients, chemotherapy-induced anemia patients, and those with iron-refractory anemia. Commercial significance is considerable given the large addressable market and chronic nature of anemia management.

Drug Class: Combination therapy comprising an intravenous iron supplement, erythropoiesis-stimulating agent, and micronutrient.

• Iron Sucrose (VENOFER): Small-molecule iron replacement; intravenous administration; mechanism of action not yet disclosed in this profile; approved globally since at least 2005.
• Human Erythropoietin Injection: Erythropoiesis-stimulating agent; mechanism of action not yet disclosed; route of administration not specified in available data.
• Vitamin C: Micronutrient cofactor; enhances iron absorption and utilization.

Modality: Small-molecule combination. Route: Iron sucrose administered intravenously. Target: Not yet disclosed. Related Therapies: Ferric carboxymaltose, epoetin alfa, epoetin beta, methoxy polyethylene glycol-epoetin beta (Mircera), ferumoxytol, and mitapivat represent competing or complementary anemia therapies.

United States: Iron sucrose (VENOFER) holds multiple FDA approvals via NDA021135 and ANDAs 208977, 212340, and 212559 from sponsors including AM REGENT, INTL MEDICATION SYS, MYLAN LABS LTD, and SANDOZ. Regulatory status of the combination program itself is not yet disclosed.

Australia: Iron sucrose approved and listed on the Australian Register of Therapeutic Goods (TGA) with PBS codes 10229J and 8807M; first listed 2005-04-01 and 2015-04-01 under sponsor Seqirus (Australia) Pty Ltd.

European Union: Regulatory status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed; sponsor is a Chinese institution (The First People's Hospital of Lianyungang).

Expected loss-of-exclusivity dates and patent expiration information are not yet disclosed.

Strategic Implications: The First People's Hospital of Lianyungang's sponsorship suggests this is a Chinese-initiated clinical investigation, potentially targeting the large anemia patient population in China. The use of established, off-patent agents (iron sucrose, erythropoietin, vitamin C) as a combination may offer regulatory and commercial advantages through potential expedited pathways if clinical data demonstrate superior efficacy or safety versus monotherapy.

Competitive Implications: This combination approach must demonstrate clear clinical superiority over existing standard-of-care regimens to gain market traction. The competitive landscape is crowded with approved agents and emerging therapies like mitapivat. Differentiation will depend on efficacy data, safety profile, dosing convenience, and cost-effectiveness relative to ferric carboxymaltose, epoetin products, and newer agents.

Future Catalysts: Primary catalyst is completion and publication of NCT06012760 results. Regulatory approval decisions in China, US, or EU would represent major milestones. Patent or exclusivity determinations for the combination formulation are unknown.

Expected Milestones: Anticipated next steps include trial completion, data analysis, regulatory submissions, and potential approval decisions. Specific timelines are not yet disclosed.